Printable Trifold Flyer - Inside Page

Dear Colleague, Rheumatologists have witnessed many
exciting and important developments in the diagnostic and
therapeutic approaches to patients with rheumatologic
disorders. For well over a decade, greater understanding of
the immunologic basis of autoimmune disorders has
resulted in the introduction of targeted biologic therapies in
the clinic. Novel agents have revolutionized the care of
patients with diverse rheumatologic disorders including
rheumatoid arthritis (RA), psoriatic arthritis (PsA),
ankylosing spondylitis (AS), systemic lupus erythematosus
(SLE), gout, vasculitis, and others. Driven by the success of
such therapeutic advances, there has been tremendous
research and interest in developing additional therapies.
Moreover, both newer as well as established therapies are
being used in novel treatment paradigms that have the
promise of achieving better clinical outcomes for our
patients. Arguably even more notable than the progress in
the therapeutic approach to rheumatic diseases has been
the important developments related to diagnosis and
stratification of patients. For example, committees from the
American College of Rheumatology (ACR), and the European
League Against Rheumatism (EULAR) have published new
classification criteria for RA as well as criteria for defining
remission. In other areas – notably safety – new data
remains an area of interest.

Because of rapid progress in the field, the latest
developments are often highlighted at scientific congresses.
In many cases, information from clinical trials is presented
at meetings many months or even years ahead of its
ultimate publication in journals. Scientific data appears in
the media or on the Internet long before it is presented in
medical journals! Because this important new information is
relevant to the clinical care of patients, it is critical that the
latest information be rapidly disseminated. Hence, there is
great value in a careful and systematic review of the latest
information, for example, data presented at rheumatology
congresses; in particular, the annual meetings of the ACR
and the EULAR. In order to accomplish this we have
assembled an outstanding faculty of superlative lecturers
who have extensive expertise in these areas.

Sincerely, Arthur Kavanaugh, MD
This activity has been planned and implemented in accordance with the
Accreditation Council for Continuing Medical Education (ACCME) standards
through the joint providership of University of California, San Diego School of
Medicine and Northern California Rheumatology Society (NCRS).  The
University of California, San Diego School of Medicine is accredited by the
ACCME for Continuing Medical Education to provide continuing medical
education for physicians.

AMA: The University of California, San Diego School of Medicine designates
this live activity for a maximum of
4.25 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.

AAPA: AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from organizations accredited by the
ACCME or a recognized state medical society. Physician assistants may
receive a maximum of
4.25 hours of Category 1 credit for completing this

Nurses: For the purpose of recertification, the American Nurses Credentialing
Center accepts AMA PRA Category 1 Credits™ issued by organizations
accredited by the ACCME. For the purpose of re-licensure, the California
Board of Registered Nursing accepts AMA PRA Category 1 Credits™ (report up
4.25 hours of credit and list “CME Category 1” as the provider number).

Disclosure: It is the policy of the University of California, San Diego School of Medicine
to ensure balance, independence, objectivity and scientific rigor. All persons involved in
the selection, development and presentation of content are required to disclose any
real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an
educational activity being delivered to learners through one of the following
mechanisms: 1) altering the financial relationship with the commercial interest, 2)
altering the individual’s control over CME content about the products or services of the
commercial interest, and/or 3) validating the activity content through independent peer
review. All persons are also required to disclose any discussions of off label/unapproved
uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from
participating in the CME activity.

Cultural and Linguistic Competency: This activity is in compliance with California
Assembly Bill 1195 which requires continuing medical education activities with patient
care components to include curriculum in the subjects of cultural and linguistic
competency. Cultural competency is defined as a set of integrated attitudes,
knowledge, and skills that enables health care professionals or organizations to care
effectively for patients from diverse cultures, groups, and communities. Linguistic
competency is defined as the ability of a physician or surgeon to provide patients who
do not speak English or who have limited ability to speak English, direct communication
in the patient’s primary language. Cultural and linguistic competency was incorporated
into the planning of this activity. Additional resources can be found on the UC San
Diego CME website.
Cancellation Policy: The course registration fee is nonrefundable. If, after registering,
you find that you are unable to attend the conference, please contact NCRS at your
earliest convenience. Space is limited and your cancellation may allow someone else to
attend in your place. It will also help ensure that we have the appropriate number of
materials. We thank you in advance for this courtesy. In the unlikely event that the
course is canceled, NCRS is responsible only for a full refund of the registration fee and
not for transportation, hotel accommodations or any miscellaneous expenses.

For further information please contact Victor Mo at NCRS:
Email: NorCalRheumatology at
Tel: (415) 735-6277 Fax: (888) 599-8812
3775 Beacon Ave Ste 100, Fremont, CA 94538
Printable Trifold Flyer - Outside Page
• We welcome the support of this activity in the form of  
educational grants or exhibitor fees.
• Exhibitor fees ranges from $1,200 to $2,500 and include a
shared  or one tabletop exhibit and one or two
complimentary registrations.
• As an exhibitor or supporter, your company or
organization will  be acknowledged on the program website
and in handout  materials.
• Please read the
UC San Diego CME Policy on Commercial
Support  and the ACCME Standards for Commercial Support.
(8AM – 8:45   Pre-Conference Topic: TBD)     
9AM         *Overview ~ Kavanaugh
9:10AM    *Rheumatoid Arthritis -
         Review of Novel Therapies,  
           ~  Mark Genovese, MD
10:10AM             Break & Exhibit

10:30AM   *EULAR Review (SLE/
          Vasculitis/ Gout/ AS),
  ~ Arthur Kavanaugh, MD
11:30AM   *PsA - New agents and
           Novel Treatment Approaches,
~ Mark Genovese, MD

12:30PM     Lunch (box lunch pick-up)
             & Exhibit

1:00PM     *ACR Review & Safety Issues/
          Other Considerations,
~ Arthur Kavanaugh, MD

2:00PM       Panel Questions & Answer,
        Session Moderator:
         ~ Arthur Kavanaugh, MD
2:30PM      Final Adjournment    

Note: * = CME events
7:30AM - 9AM   Registration, Breakfast, Exhibit

8 AM      Pre-Conference Topic:
     Reimbursement Realities 2015 -
     Elizabeth Woodcock, MBA, FACMPE, CPC
9AM         *Overview ~ Arthur Kavanaugh MD
9:10AM    *Rheumatoid Arthritis -
    Review of Novel Therapies,
      ~ Mark Genovese MD

10:10AM   Break, Exhibit

10:35AM   *EULAR Review (SLE/Vasculitis
          / Gout/ AS)
, Kavanaugh MD

11:35AM   *PsA - New agents and
Novel Treatment Approaches,
Genovese MD

12:35AM - 1 PM - Box Lunch, Exhibit

1:00PM     *ACR Review & Safety Issues/
  Other Considerations,
Kavanaugh, MD

2:00PM       Panel Questions & Answer,
   Session Moderator: Kavanaugh MD
2:30PM      Final Adjournment    
*Note: = CME events
Registration powered by RegOnline